G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting

G1 Therapeutics, Inc. announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate sacituzumab govitecan on...

Related Keywords

United States ,Chicago ,Illinois ,American , ,American Society Of Clinical Oncology ,Therapeutics Inc ,Clinical Oncology ,Presentation Details ,Trilaciclib Combined ,Sacituzumab Govitecan ,Metastatic Triple Negative Breast Cancer ,Updated Phase ,Efficacy Results Seneviratne ,Breast Cancer Metastatic June ,